<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of the present study was to investigate the usefulness of <z:chebi fb="0" ids="23359">colchicine</z:chebi> in the treatment of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>Ten patients suffering from <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome were selected for this purpose </plain></SENT>
<SENT sid="2" pm="."><plain>The patients were treated with 1 mg/day of <z:chebi fb="0" ids="23359">colchicine</z:chebi> associated with 1 mg of betametasone during the initial florid phase of the disease </plain></SENT>
<SENT sid="3" pm="."><plain>After the <z:hpo ids='HP_0011009'>acute</z:hpo> phase, betametasone was withdrawn </plain></SENT>
<SENT sid="4" pm="."><plain>The patients were observed for a period ranging from 5 to 23 months </plain></SENT>
<SENT sid="5" pm="."><plain>Biochemical and immunological parameters were measured at time 0 and every month in order to monitor the disease and the possible side effects of <z:chebi fb="0" ids="23359">colchicine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had a satisfactory control of the disease without showing any toxic effect </plain></SENT>
</text></document>